Shilpa Medicare has announced a long-term development and commercial manufacturing agreement with Switzerland-based NXI Therapeutics AG, strengthening its position in the fast-expanding global CDMO and specialty therapeutics market.
Under the agreement, Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support.
The partnership covers the full drug development lifecycle—from early-stage work through to potential commercialization—positioning Shilpa as a long-term strategic manufacturing partner for NXI’s program.
The deal targets the rapidly growing autoimmune and immune-modulation segment, one of the most active areas in global biopharma innovation. By entering the program early, Shilpa further deepens its exposure to high-value pipelines with scalable commercial potential.
This marks the third named partnership disclosed by Shilpa in the past year, underscoring accelerating demand from Western biotech firms for its integrated R&D and GMP manufacturing capabilities.
While financial terms were not disclosed, the agreement includes milestone-linked expansion potential and could evolve into a multi-year commercial supply relationship, subject to clinical and regulatory progress.
Commenting on the collaboration, Vishnukanth Bhutada, Managing Director, Shilpa Medicare Limited, said: “This collaboration reinforces Shilpa’s transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle.
"We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform.”
Ruben Herrendorff, CEO, NXI Therapeutics AG, added: “Shilpa’s scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones.”
With expanding biologics capabilities, advanced GMP infrastructure in India, and a growing global client base, Shilpa continues to cement its role as a key partner for innovative drug developers in high-growth therapeutic areas.
